Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins

被引：26

作者：

Bernardo, Lidice ^{[1
]}

Hermida, Lisset ^{[2
]}

Martin, Jorge ^{[2
]}

Alvarez, Mayling ^{[1
]}

Prado, Irina ^{[1
]}

Lopez, Carlos ^{[2
]}

Martinez, Rafael ^{[2
]}

Rodriguez-Roche, Rosmari ^{[1
]}

Zulueta, Aida ^{[2
]}

Lazo, Laura ^{[2
]}

Rosario, Delfina ^{[1
]}

Guillen, Gerardo ^{[2
]}

Guzman, Maria G. ^{[1
]}

机构：

[1] PAHO, WHO Collaborat Ctr Viral, Dept Virol, Pedro Kouri TRop Med Inst IPK, Havana, Cuba

[2] Ctr Gene Engn & Biotechnol, Havana 10600, Cuba

来源：

ARCHIVES OF VIROLOGY | 2008年 / 153卷 / 05期

关键词：

D O I：

10.1007/s00705-008-0050-9

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The suitability of dengue 2 envelope domain III recombinant fusion proteins [(fusion (PD5) and insertion (PD3) variants)] for inducing functional antibodies and a protective immune response in nonhuman primates has been reported. However, the evaluation of the antibody response after immunization did not correlate with the protection data as measured by viremia detection. Here, we characterized the anamnestic immune response after viral challenge in monkeys immunized with the dengue 2 recombinant proteins in an attempt to define correlates of protection useful for vaccine studies. Monkeys immunized with PD5 (most protected group) exhibited an earlier increase in the anti-DENV-2 IgM response after challenge compared to control animals. Hemagglutination-inhibiting (HAI) antibodies were increased significantly earlier in PD5-immunized animals compared to those immunized with PD3. The fully protected monkeys showed the earliest HAI antibody response. These results underline the usefulness of the anamnestic antibody response for supporting protection data. The induction of an early HAI and IgM antibody response after challenge suggest a protective role against dengue virus (DENV) infection in monkeys, supporting their use as correlates of protection in vaccine studies.

引用

页码：849 / 854

页数：6

共 30 条

[1]

Alvarez M, 2005, DENGUE B, V29, P1

[2]

ANTUNEZ MP, 1997, HYBRIDOMA, V16, P347

[3] Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge [J].

Bray, M ;

Men, RH ;

Lai, CJ .

JOURNAL OF VIROLOGY, 1996, 70 (06) :4162-4166

[4] ANTIBODIES AGAINST DENGUE VIRAL-PROTEINS IN PRIMARY AND SECONDARY DENGUE HEMORRHAGIC-FEVER [J].

CHURDBOONCHART, V ;

BHAMARAPRAVATI, N ;

PEAMPRAMPRECHA, S ;

SIRINAVIN, S .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 44 (05) :481-493

[5] TECHNIQUES FOR HEMAGGLUTINATION AND HEMAGGLUTINATION-INHIBITION WITH ARTHROPOD-BORNE VIRUSES [J].

CLARKE, DH ;

CASALS, J .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1958, 7 (05) :561-573

[6] ANALYSIS OF C-TERMINALLY TRUNCATED DENGUE-2 AND DENGUE-3 VIRUS ENVELOPE GLYCOPROTEINS - PROCESSING IN INSECT CELLS AND IMMUNOGENIC PROPERTIES IN MICE [J].

DELENDA, C ;

STAROPOLI, I ;

FRENKIEL, MP ;

CABANIE, L ;

DEUBEL, V .

JOURNAL OF GENERAL VIROLOGY, 1994, 75 :1569-1578

[7] The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers [J].

Durbin, Anna P. ;

McArthur, Julie ;

Marron, Jennifer A. ;

Blaney, Joseph E., Jr. ;

Thumar, Bhavin ;

Wanionek, Kim ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

HUMAN VACCINES, 2006, 2 (04) :167-173

[8] rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers [J].

Durbin, AP ;

Whitehead, SS ;

McArthur, J ;

Perreault, JR ;

Blaney, JE ;

Thumar, B ;

Murphy, BR ;

Karron, RA .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05) :710-718

[9] Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine [J].

Edelman, R ;

Wasserman, SS ;

Bodison, SA ;

Putnak, RJ ;

Eckels, KH ;

Tang, D ;

Kanesa-Thasan, N ;

Vaughn, DW ;

Innis, BL ;

Sun, W .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06) :48-60

[10] Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins [J].

Falconar, AKI .

ARCHIVES OF VIROLOGY, 1999, 144 (12) :2313-2330

← 1 2 3 →